Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

Business Leaders

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance Pro.CalendarSectors 
HomeAll NewsMost read newsBusiness Leaders Biography

Summary 
Presently, Mauro Teixeira Sampaio holds the position of VP-Legal, Compliance, Human Resources, M&A at Rede D'Or São Luiz SA and Chairman for Distribuidora de Produtos Petroleo Ipiranga SA.

He is also on the board of Qualicorp Consultoria e Corretora de Seguros SA and Ggsh Participaçoes SA.

In his past career he occupied the position of Partner at Barbosa, Müssnich & Aragão Advogados.

He received a graduate degree from Universidade Estadual do Rio de Janeiro.




Current positions of Mauro Teixeira Sampaio 
Mauro Teixeira Sampaio : Personal Network 
Most Read News 
10/12CATHIE WOOD : ARK Invest's Wood warns upcoming economic downturn in China 'obvious'
RE
10/15JACK DORSEY : Square CEO Dorsey says looking to build a bitcoin mining system - tweet
RE
10/11JAMIE DIMON : JPMorgan's Dimon blasts bitcoin as 'worthless', due for regulation
RE
10/20JACK MA : Alibaba founder Ma spotted in Mallorca in rare trip abroad after China scrutiny
RE
10/22WARREN BUFFETT : Generali closer to controlling Cattolica after Buffett tenders shares - source
RE
10/17ELON MUSK : Tesla's Musk dials into Volkswagen executive conference
RE
10/21ALEXANDRE RICARD : Pernod Ricard 1Q Sales Soar as Drinkers Head to the Bars
DJ
10/13WARREN BUFFETT : Buffett-backed Nubank turns a profit in Brazil
RE
10/18BILL GATES : Electric vehicle battery startup ONE backed by BMW, Gates-led firm
RE
10/25ELON MUSK : WRAPUP 3-Tesla zooms past $1 trillion market cap on bet that the EV future is now
RE
More news


© 2021 People and Ownership :   
Mauro Teixeira Sampaio : Connections 


Latest news about Mauro Teixeira Sampaio 
06/01SynAct Pharma Updates Phase II study with AP1189
CI
03/18SynAct Pharma AB Initiates Dosing in Part 2 of the Clinical Phase II Study with AP1189 in Covid-19 Infected Patients UK Version
CI
2020SYNACT PHARMA INITIATES RESOVIR : Scientific and clinical Collaboration to Explore AP1189 in Viral Infections
CI
More news